Portal de investigação
CD44v6 High Membranous Expression Is a Predictive Marker of Therapy Response in Gastric Cancer Patients
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Almeida, GM
- Pereira, C
- Park, JH
- Lemos, C
- Campelos, S
- Martins, D
- Gonçalves, G
- Leitao, D
- Neto, JL
- Andre, A
- Borges, C
- Almeida, D
- Lee, HJ
- Kong, SH
- Kim, WH
- Almeida, R.
- Yang, HK
Unidades de investigação
Abstract
In gastric cancer (GC), biomarkers that define prognosis and predict treatment response remain scarce. We hypothesized that the extent of CD44v6 membranous tumor expression could predict prognosis and therapy response in GC patients. Two GC surgical cohorts, from Portugal and South Korea (n = 964), were characterized for the extension of CD44v6 membranous immuno-expression, clinicopathological features, patient survival, and therapy response. The value of CD44v6 expression in predicting response to treatment and its impact on prognosis was determined. High CD44v6 expression was associated with invasive features (perineural invasion and depth of invasion) in both cohorts and with worse survival in the Portuguese GC cohort (HR 1.461; 95% confidence interval 1.002-2.131). Patients with high CD44v6 tumor expression benefited from conventional chemotherapy in addition to surgery (p < 0.05), particularly those with heterogeneous CD44v6-positive and -negative populations (CD44v6_3+) (p < 0.007 and p < 0.009). Our study is the first to identify CD44v6 high membranous expression as a potential predictive marker of response to conventional treatment, but it does not clarify CD44v6 prognostic value in GC. Importantly, our data support selection of GC patients with high CD44v6-expressing tumors for conventional chemotherapy in addition to surgery. These findings will allow better stratification of GC patients for treatment, potentially improving their overall survival.
Dados da publicação
- ISSN/ISSNe:
- 2227-9059, 2227-9059
- Tipo:
- Article
- Páginas:
- 1249-
- Link para outro recurso:
- www.scopus.com
Biomedicines MDPI AG
Citações Recebidas na Web of Science: 3
Citações Recebidas na Scopus: 4
Documentos
- Não há documentos
Filiações
Keywords
- stomach neoplasms; genetic heterogeneity; biomarkers; drug therapy; conventional chemotherapy; gastric surgery
Financiamento
Proyectos asociados
The role of hepatocyte apoptosis markers in predicting the histological and serological activity in steatohepatitis
Investigador Principal: Maria de Fátima Machado Henriques Carneiro
Estudo Clínico Académico . 2021
E-cadherin and CD44v6 in Gastric Cancer: Role, crosstalk and clinical implications
Investigador Principal: Carla Isabel Gonçalves de Oliveira
Estudo Clínico Académico . 2021
Gastric Cancer Morphological, Immunophenotypic and molecular heterogeneity
Investigador Principal: Maria de Fátima Machado Henriques Carneiro
Estudo Clínico Académico . 2020
Citar a publicação
Almeida GM,Pereira C,Park JH,Lemos C,Campelos S,Gullo I,Martins D,Gonçalves G,Leitao D,Neto JL,Andre A,Borges C,Almeida D,Lee HJ,Kong SH,Kim WH,Carneiro F,Almeida R,Yang HK,Oliveira C. CD44v6 High Membranous Expression Is a Predictive Marker of Therapy Response in Gastric Cancer Patients. Biomedicines. 2021. 9. (9):p. 1249-1249. IF:4,757. (2).
